Alleviation of isolated nail lichen planus by the JAK1/2 inhibitor Baricitinib: a case report

被引：4
|
作者：
He, Juan [1 ]
Weng, Tengyu [1 ]
Zhu, Wenwei [1 ]
Yang, Yi [2 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Dermatol, Beijing, Peoples R China
[2] Third Med Ctr Chinese Peoples Liberat Army, Dept Dermatol, Beijing, Peoples R China
来源：
JOURNAL OF DERMATOLOGICAL TREATMENT | 2023年 / 34卷 / 01期
关键词：
D O I：
10.1080/09546634.2023.2274816
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Successful treatment of recalcitrant follicular lichen planus (lichen planopilaris) with the topical JAK 1/2 inhibitor ruxolitinib
    Fetter, Tanja
    Wilsmann-Theis, Dagmar
    de Vos-Hillebrand, Luka
    Novak, Natalija
    Wenzel, Joerg
    JEADV CLINICAL PRACTICE, 2025, 4 (01): : 220 - 223
  • [22] PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report
    Lim, Olivia
    Maher, Eamonn
    Miller, Daniel D.
    DRUGS IN R&D, 2024, 24 (02) : 353 - 357
  • [23] Jak1/2 inhibitor baricitinib as a potential therapy in a patient with gain-of-function mutation in stat1
    Meesilpavikkai, K.
    Dik, W. A.
    Schrijver, B.
    Nagtzaam, N. M. A.
    Posthumus-van Sluijs, S. J.
    Van Hagen, P. M.
    Dalm, V. A. S. H.
    MEDICAL MYCOLOGY, 2018, 56 : S78 - S78
  • [24] The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib
    Choy, E. H. S.
    Miceli-Richard, C.
    Gonzalez-Gay, M. A.
    Sinigaglia, L.
    Schlichting, D. E.
    Meszaros, G.
    de la Torre, I.
    Schulze-Koops, H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) : 694 - 704
  • [25] Successful treatment of nail lichen planus with tofacitinib: a case report and review of the literature
    Huang, Jundong
    Shi, Wei
    FRONTIERS IN MEDICINE, 2023, 10
  • [26] Clinical characteristics and management outcomes in isolated nail lichen planus: A retrospective case series
    Singal, Archana
    Gaurav, Vishal
    Kaur, Ishmeet
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2024, 90 (03): : 329 - 335
  • [27] Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series
    Kwon, Il Joo
    Kim, Song-Ee
    Kim, Soo-Chan
    Lee, Sang Eun
    JOURNAL OF DERMATOLOGY, 2024, 51 (03): : 441 - 447
  • [28] JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus
    Wenzel, Joerg
    van Holt, Nadine
    Maier, Judith
    Vonnahme, Maria
    Bieber, Thomas
    Wolf, Dominik
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (06) : 1281 - 1283
  • [29] JAK1/2 Inhibition in Severe TAFRO Syndrome: A Case Report
    Killian, Martin
    Viel, Sebastien
    Chalayer, Emilie
    Forest, Fabien
    Grange, Sylvain
    Bonnefoy, Pierre-Benoit
    Oksenhendler, Eric
    Cathebras, Pascal
    Paul, Stephane
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (05) : 719 - +
  • [30] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
    Vaddi, Kris
    Sarlis, Nicholas J.
    Gupta, Vikas
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
12345